Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis www.blackprwire.com
(Black PR Wire) Kansas City, MO - Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from its Phase IIa Clinical Trial of VBI-S in septic shock patients. Each of the thirteen (13) patients treated so far in the trial met the primary goal which was an elevation of mean arterial blood pressure by at least ...
DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Septic Shock,
See the article here: https://beststartup.us/?p=6700
Hypovolemic Shock Market: Market Analysis, Leading Companies, Emerging Drugs, Epidemiology Forecast and Competitive Analysis by DelveInsight
World Sepsis Pipeline Insight 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs - ResearchAndMarkets .com
"Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with our Sepsis Treatment, VBI-S, for the elevation of blood pressure (treating persistently low hypotension) in Covid-19 induced Septic Shock. Most COVID patients die of septic shock. In early studies, VBI-S improved blood pressure and oxygenation of septic shock patients when all other measures had failed. See Press Release immediately below."
If customers can’t find it, it doesn’t exist. Clearly list and describe the services you offer. Also, be sure to showcase a premium service.
Open today | 09:00 am – 05:00 pm |
Copyright © 2022 Vivacelle Bio Inc. - All Rights Reserved.
Powered by GoDaddy Website Builder
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.